Opus Genetics Inc. (IRD)
NASDAQ: IRDHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
IRD stock chart
Technical analysisKey statistics
All statistics- Market cap
- $385.65M
- EPS (TTM)
- -$1.48
- Dividend yield
- None
- 52-week range
- 1.88 – 7.07
- Day range
- 3.89 – 4.05
- Volume / Avg
- 1.19M / 2.56M
- Beta
- —
- Shares outstanding
- 96.65M
52-week range
IRD stock today
On Nov 20, IRD ended the session at $3.99, shedding $0.09 (2.21%), versus the S&P 500's 3.70% decline. Trading was light, with 1.19M shares changing hands, about 46% of the average daily volume. Shares are 43.6% below their 52-week high of $7.07, set on Sep 9, 2026 and 112.2% above the 52-week low of $1.88, in the middle of the past year's range.
IRD is up 98.5% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 108.9%. Opus Genetics has posted a net loss over the last twelve months (EPS of -$1.48), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Opus Genetics
Company profileOpus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal dominant retinitis pigmentosa caused by RHO mutations; OPGx-RDH12 that is designed to restore protein expression and halt functional deterioration in patients with retinal dystrophy caused by mutations in the retinal dehydrogenase gene; OPGx-MERTK, an AAV vector for the treatment of MERTK IRD; OPGx-NMNAT1, a gene augmentation therapy designed to halt functional deterioration in pediatric patients with retinal degenerative disease caused by mutations in the nicotinamide mononucleotide adenylyltransferase 1 gene; and OPGx-CNGB1, an AAV gene therapy for retinitis pigmentosa due to mutations in the CNGB1 gene.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. George Magrath M.B.A., M.D., M.S.
- Headquarters
- Durham, NC
- Employees
- 27
- Website
- opusgtx.com
Financial highlights
Full financialsIn fiscal 2025, Opus Genetics generated $14.2 million in revenue, up 29.1% from fiscal 2024. Opus Genetics reported a net loss of $49.6 million, compared with a loss of $57.5 million a year earlier. Operating margin was -271.9%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $14.20M | $10.99M | $19.05M | $39.85M | $589.00K |
| Growth | +29.15% | -42.30% | -52.20% | +6665.70% | — |
| Net income | $-49.59M | $-57.53M | $-9.99M | $17.89M | $-56.69M |
| EPS (diluted) | $-0.80 | $-2.15 | $-0.46 | $0.87 | $-3.82 |
Analyst forecast
ForecastConsensus (17 analysts)
strong_buy
Avg. price target
$13.94+249.37%
- Strong buy 3
- Buy 14
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 11, 2026
- EPS actual vs est.
- $-0.46 vs $-0.14
- Surprise
- -228.57%
IRD news
All IRD news- Opus Genetics Doses First Participant Following FDA Clearance Of OPGx-RDH12 IND; Stock DownNasdaqIRD, UHAL.B
- Opus Genetics Announces First Participant Dosed in Phase 1/2 Clinical Trial of OPGx-RDH12 Gene Therapy for Rare Inherited Childhood BlindnessGlobeNewswire
- Opus Genetics Announces Financial Results for Third Quarter 2026 and Provides Corporate UpdateGlobeNewswire
- Opus Genetics Completes Dosing in Cohort 2 of Phase 1/2 Clinical Trial of OPGx-BEST1 Gene Therapy for Inherited Retinal DiseasesGlobeNewswire
- Opus Genetics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire
- Opus Genetics Eyes 2029 Runway as Presbyopia Drop Wins FDA ApprovalNasdaq
- Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of PresbyopiaGlobeNewswire
- Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026GlobeNewswire
Opus Genetics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| AVTXAvalo Therapeutics Inc. | 6.76 | +0.15% | $390.88M | vs IRD |
| PHATPhathom Pharmaceuticals Inc. | 4.66 | -8.27% | $378.82M | vs IRD |
| OCSOculis Holding AG | 7.06 | -5.11% | $393.35M | vs IRD |
| PBYIPuma Biotechnology Inc | 7.05 | -0.98% | $364.47M | vs IRD |
| ASPEAspen Neuroscience Inc. | 12.42 | +0.24% | $361.16M | vs IRD |
| PEPGPepGen Inc. | 3.78 | -3.82% | $356.31M | vs IRD |
| OVIDOvid Therapeutics Inc. | 2.20 | -5.98% | $415.21M | vs IRD |
| CRMDCorMedix Inc. | 5.27 | +3.74% | $419.16M | vs IRD |
Indexes, lists and sector
Opus Genetics stock FAQ
What is Opus Genetics's stock price today?
IRD last traded at $3.99 as of Nov 20, 4:00 PM EST, down 2.21% on the day. Prices are delayed at least 15 minutes.
Does Opus Genetics pay a dividend?
No. Opus Genetics does not currently pay a regular cash dividend.
Who is Opus Genetics's CEO?
Dr. George Magrath M.B.A., M.D., M.S. is the chief executive officer of Opus Genetics Inc., which has about 27 employees.
Has IRD ever split its stock?
Yes. The most recent IRD stock split was a 1-for-4 split on Nov 6, 2020, one of 3 splits on record.
What is the IRD 52-week high?
The 52-week high for IRD is $7.07 and the 52-week low is $1.88. The stock is currently 43.6% below its high.